Roivant Sciences Ltd.
ROIV
Kedudukan dalam Saham
#979
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Harga Saham
$33.73
Disegerakkan terakhir: 2026-07-31
Modal Pasaran
$24.37B
Perubahan (1 hari)
-2.28%
Perubahan (1 tahun)
88.77%
Negara
GB
Perdagangan Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
Hasil untuk Roivant Sciences Ltd. (ROIV)
Hasil pada Jun 2026 TTM: $7.53M
Menurut laporan kewangan terkini daripada Roivant Sciences Ltd., hasil semasa syarikat (TTM) ialah $7.53M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $32.71M penurunan berbanding hasil pada tahun 2023 iaitu $61.28M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Roivant Sciences Ltd. dari 2020 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $7.53M | -74.07% |
| 2025 | $29.05M | -11.19% |
| 2024 | $32.71M | -46.62% |
| 2023 | $61.28M | 10.84% |
| 2022 | $55.29M | 132.34% |
| 2021 | $23.80M | -64.85% |
| 2020 | $67.69M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 167,508.87% |
US
|
|
| $2.23B | 29,480.46% |
US
|
|
| $15.74B | 208,932.49% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 79,842.74% |
NL
|
